CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Develop

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

Publications

Percutaneous Liquid Ablation Agent for Tumor Treatment and Drug Delivery

Sci Transl Med., Feb 2021 

Here, the study showed that a successful injection of an ionic liquid into tissue under image guidance lead to ablation of tumors in response to the injected ionic liquid, and persistence (28 days) of coinjected chemotherapy with the ionic liquid in the ablation zone.

Clinical Translation of Choline and Geranic Acid Deep Eutectic Solvent

Bioeng Transl Med., October 2020 

Here, we describe the first report of clinical translation of CAGE from the lab into the clinic for the treatment of rosacea, a common chronic inflammatory skin disorder that affects the face. We describe the seven steps of clinical translation including (a) scale-up, (b) characterization, (c) stability analysis, (d) mechanism of action, (e) dose determination, (f) GLP toxicity study, and

(g) human clinical study. 

A Long-Lasting Sanitizing Skin Protectant based on CAGE, a Choline and Geranic Acid Eutectic

medRxiv, August 2020

Herein, we describe a skin protectant, IonLASTTM, based on an ionic liquid/deep eutectic solvent, formed by GRAS materials, choline and geranic acid (CAGE, CG-101), that provides protection for at least 4h after a single application. IonLASTTM was formulated as a gel that facilitates easy application on the skin. Tolerance of CG-101 was substantiated through a study in human volunteers. In vitro studies confirmed that IonLASTTM effectively inactivates a human coronavirus hCoV229E. A second human clinical study established that a single application of IonLASTTM imparts protection against microbes that lasts up to several hours.  

Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations

Science Advances, July 2020

The limitations of topical nucleic acid delivery were circumvented by using an ionic liquid (IL) combination to successfully deliver a small interfering RNA (siRNA)-based treatment directly to the skin in a mouse model of psoriasis, significantly reducing levels of inflammatory cytokines and symptoms of psoriasis without systemic side effects. 


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway

Learn more